(Photo credit: BryoLogyx, Inc.) DANVILLE, CA (October 13)—BryoLogyx, Inc. announced today that it has chemically-synthesized the bryostatin-1 molecule (above) under FDA’s Good Manufacturing Practice (GMP) regulations. Its manufacture is in preparation for clinical trials to study its potential to improve the response to cancer immunotherapies and additional preclinical research. The molecule was originally sourced from a marine invertebrate organism by the NCI. Bryostatin-1 is a potent, highly complex macrolide that had proved nearly intractable to chemically synthesize. The manufacture was based on a fully synthetic process developed at Stanford University by Dr. Paul Wender and colleagues www.bryologyx.com.
BryoLogyx Inc. has entered into two agreements with Neurotrope, Inc. to acquire Neurotrope’s preclinical data and drug product bryostatin-1 for an immuno-oncology application, and to supply Neurotrope with synthetic bryostatin-1 for clinical trials and commercialization for the treatment of Alzheimer’s disease and other neurodegenerative diseases. Neurotrope has been developing bryostatin-1 under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). Financial terms were not disclosed.
Aphios Corporation today announced that it was granted United States Patent No. 10,485,766 for the oral administration of Bryostatin-1 nanoparticles for the treatment of neurodegenerative diseases such as Huntington’s Disease, Parkinson's disease, Multiple Sclerosis, Down syndrome and Alzheimer's disease.
Drug developer Neurotrope Inc’s shares tumbled nearly 80% on Monday after the company said its experimental treatment for Alzheimer’s disease did not meet the main goal of a mid-stage study.
Neurotrope Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that it has initiated dosing in the final patient in the Company's randomized, double-blind, placebo-controlled, confirmatory Phase 2 clinical trial of Bryostatin-1 in moderate to severe AD patients not on memantine. A total of 108 patients were enrolled into the study.
Neurotrope Announces Cooperative Research and Development Agreement for Bryostatin-1 with NCI